Balance Sheet Guard Therapeutics International AB
Equities
GUARD
SE0021181559
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.00 SEK | 0.00% | +4.32% | -18.99% |
08-29 | First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER | CI |
08-27 | Guard Therapeutics Plans New SEK80 Million Rights Issue to Fund Kidney Drug Study | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 53.97M | 90.04M | 189M | 201M | 83.74M | |||||
Total Cash And Short Term Investments | 53.97M | 90.04M | 189M | 201M | 83.74M | |||||
Accounts Receivable, Total | - | - | - | - | - | |||||
Other Receivables | 1.38M | 709K | 931K | 897K | 667K | |||||
Total Receivables | 1.38M | 709K | 931K | 897K | 667K | |||||
Prepaid Expenses | 526K | 427K | 872K | 685K | 819K | |||||
Other Current Assets, Total | -1K | - | - | 1K | - | |||||
Total Current Assets | 55.87M | 91.18M | 190M | 203M | 85.23M | |||||
Gross Property Plant And Equipment | 2.65M | 2.02M | 2.02M | 2.02M | - | |||||
Accumulated Depreciation | -2.14M | -1.98M | -1.99M | -2.01M | - | |||||
Net Property Plant And Equipment | 516K | 44K | 29K | 15K | - | |||||
Other Intangibles, Total | 7.32M | - | - | - | - | |||||
Deferred Charges Long-Term | 0 | - | - | - | - | |||||
Other Long-Term Assets, Total | - | - | - | -1K | - | |||||
Total Assets | 63.71M | 91.22M | 190M | 203M | 85.23M | |||||
Liabilities | ||||||||||
Accounts Payable, Total | 2.52M | 2.98M | 6.29M | 11.22M | 5.49M | |||||
Accrued Expenses, Total | 2.42M | 3.1M | 3.92M | 10.79M | 10.56M | |||||
Current Portion of Leases | 176K | - | - | - | - | |||||
Current Income Taxes Payable | - | 222K | 270K | 392K | 268K | |||||
Other Current Liabilities | 178K | 201K | 466K | 290K | 294K | |||||
Total Current Liabilities | 5.3M | 6.5M | 10.94M | 22.7M | 16.61M | |||||
Long-Term Leases | 15K | - | - | - | - | |||||
Deferred Tax Liability Non Current | - | - | - | - | - | |||||
Other Non Current Liabilities | 5.78M | 5.03M | 3.72M | 2.55M | 1.88M | |||||
Total Liabilities | 11.09M | 11.54M | 14.66M | 25.24M | 18.49M | |||||
Common Stock, Total | 52.36M | 4.26M | 6.86M | 10.06M | 10.06M | |||||
Additional Paid In Capital | 45.42M | 443M | 619M | 730M | 733M | |||||
Retained Earnings | -45.16M | -368M | -450M | -563M | -676M | |||||
Comprehensive Income and Other | - | - | -1K | -1K | -1K | |||||
Total Common Equity | 52.62M | 79.69M | 176M | 177M | 66.73M | |||||
Total Equity | 52.62M | 79.69M | 176M | 177M | 66.73M | |||||
Total Liabilities And Equity | 63.71M | 91.22M | 190M | 203M | 85.23M | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 3.08M | 4.26M | 6.86M | 10.06M | 10.06M | |||||
ECS Total Common Shares Outstanding | 3.08M | 4.26M | 6.86M | 10.06M | 10.06M | |||||
Book Value / Share | 17.07 | 18.71 | 25.62 | 17.63 | 6.63 | |||||
Tangible Book Value | 45.3M | 79.69M | 176M | 177M | 66.73M | |||||
Tangible Book Value Per Share | 14.7 | 18.71 | 25.62 | 17.63 | 6.63 | |||||
Total Debt | 191K | 0 | 0 | 0 | 0 | |||||
Net Debt | -53.78M | -90.04M | -189M | -201M | -83.74M | |||||
Debt Equivalent Oper. Leases | 176K | - | - | - | - | |||||
Account Code - Inventory Valuation | 3 | 3 | 3 | 3 | 3 | |||||
Machinery, Total | 2.05M | 2.02M | 2.02M | 2.02M | - | |||||
Full Time Employees | - | 7 | 10 | 12 | 11 |